Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review

Chia Jie Tan1 · Samantha Yin Ching Yip1 · Raymond Javan Chan2 · Lita Chew1,3 · Alexandre Chan3,4

Received: 20 June 2021 / Accepted: 9 August 2021 / Published online: 23 August 2021
© The Author(s) 2021

Abstract

Purpose The purpose of this study is to investigate how different cancer-related symptoms influence work outcomes among cancer survivors.

Methods A literature search was performed in PubMed, EMBASE, CINAHL, PsycINFO, and Scopus to identify studies published between 1st January 1999 and 30th October 2020 that investigated the impact of specific cancer-related symptoms on work outcomes among cancer survivors who have completed primary antineoplastic treatment. Study findings were extracted and grouped by symptoms and work outcomes, allowing comparison of associations between these outcomes.

Results Seventy-three articles representing 68 studies were eligible for inclusion. From these studies, 27 cancer-related symptoms, 9 work outcomes, and 68 unique associations between specific symptoms and work outcomes were identified. Work status (return to work and employment rates) was most commonly studied, and symptom burden was mainly measured from the patient’s perspective. Higher symptom burden was generally associated with trends of poorer work outcomes. Significant associations were reported in most studies evaluating body image issues and work status, oral dysfunction and work status, fatigue and work ability, and depression and work ability.

Conclusion Several cancer-related symptoms were consistently associated with inferior work outcomes among cancer survivors. Body image issues and oral dysfunction were shown to be associated with poorer employment rates, while fatigue and depression were linked to lower levels of work performance.

Implications for Cancer Survivors Failure to return to work and decreased productivity post-cancer treatment can have negative consequences for cancer survivors and society at large. Findings from this review will guide the development of work rehabilitation programs for cancer survivors.

Protocol registration PROSPERO identifier CRD42020187754

Keywords Employment rate · Return to work · Absenteeism · Presenteeism · Work productivity · Symptom burden

Introduction

With improved long-term survival rates of cancer, work and employment have emerged as increasingly prominent issues among cancer survivors. Across a range of various cancers, approximately 40% of cancer survivors do not return to work after completion of treatment [1]. Cancer survivors who remain employed are also more likely to miss work, reduce working hours, or report limitations at work compared to their non-cancer counterparts [1, 2]. Furthermore, cancer survivors have been reported to be less productive in unpaid components of work, such as homemaking and volunteering [3]. The ability of cancer survivors to resume normal levels of productivity is crucial for both survivors and society at large. From a societal

1 Department of Pharmacy, National University of Singapore, Singapore, Singapore
2 Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia
3 Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore
4 Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 101 Theory, Suite 100, Irvine, CA 92612, USA

Alexandre Chan
a.chan@uci.edu
perspective, inferior work outcomes among cancer survivors lead to productivity loss, which was estimated to cost US$3593 per capita annually in the USA [4].

Among cancer survivors, inferior work outcomes post-treatment result from a mismatch between an individual’s functional capabilities and work demands [5]. We speculate that cancer survivors often suffer from impaired functional capabilities due to lingering symptoms from cancer and antineoplastic treatment. This is supported by empirical evidence from published studies that have reported that cancer survivors continue to face mental and physical difficulties at work and were more likely to quit due to cancer-related disabilities [6, 7]. These issues could be addressed by rehabilitative care, which has been shown to facilitate return-to-work (RTW) and reduce early retirement among cancer survivors [8, 9].

Rehabilitative care encompasses a wide range of services that aim to mitigate symptom burden and functional impairments among cancer survivors. While rehabilitative care is specific to the individual needs of patients, survivorship services targeting cancer-related symptoms that strongly impact work outcomes should be prioritized when developing work rehabilitation programs, especially in resource-constrained healthcare settings. A comprehensive understanding and comparison of how specific cancer-related symptoms influence work outcomes is therefore crucial. Despite the abundance of observational studies that have examined the relationship between specific cancer-related symptoms and work outcomes, most systematic reviews have not focused on symptom burden [10–12] or did not identify the impact of specific symptoms [13, 14].

This systematic review, therefore, aims to describe and compare how different cancer-related symptoms affect work outcomes among cancer survivors based on findings reported in the primary literature, allowing the identification of symptoms that are closely linked to poor work outcomes. Besides guiding the prioritization of survivorship services for work rehabilitation programs, the findings of this review will also provide insights into the current state of research on the relationship between symptom burden and work outcomes, identifying gaps in the field that need to be addressed.

Methods

The protocol for this systematic review has been registered on PROSPERO (ID: CRD42020187754) and reporting of the review is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15].

Search strategy

Literature search was performed in the PubMed, EMBASE, CINAHL, PsycINFO, and Scopus databases for studies published from 1st January 1999 to 30th October 2020 with the final search performed prior to data analysis. Initial searches were conducted using a combination of MeSH terms and free-text terms related to cancer survivors and work-related outcomes separately, with each term combined with “or.” Subsequently, the results of both searches were collectively combined with “and.” The search syntax was then adopted per database (Supplementary Material 1).

Eligibility criteria

Studies that quantified the impact of symptom burden on work outcomes among adult cancer survivors who had completed primary treatment (surgery, cytotoxic chemotherapy, and/or radiotherapy) were eligible. If the treatment status of study participants was not specified, work outcomes should have been evaluated at least 12 months from diagnosis, when the primary treatment for most cancer diagnoses would have been completed. Studies were excluded if they included survivors of childhood cancer or if patients were undergoing palliative treatment during the assessment of work outcomes.

Eligible studies also had to identify a specific symptom or symptoms localized in a specific body region as the aim of this review was to provide insights on specific types of services that should be prioritized in work rehabilitation programs. Therefore, studies that only evaluated the exposure as a collation of symptoms (for example, a summation score from a quality-of-life questionnaire covering various symptoms) were not eligible. Furthermore, studies were excluded if work was measured as a part of a composite outcome that included non-work components such as schooling.

Studies that examined the effectiveness of interventions in alleviating symptom burden were also excluded as the findings would not have reflected the actual impact of symptoms on work outcomes. Other exclusion criteria were qualitative studies, systematic and narrative reviews, books, commentaries, editorials, magazine articles, and conference proceedings or abstracts. Only articles published in English with full texts available were reviewed.

Study selection

After the removal of duplicates, search results were first screened based on the title and abstract. Full texts of potentially relevant articles were subsequently retrieved and reviewed for eligibility. The screening process was carried
out by CJT and SYCY independently with discrepancies reconciled by discussion or adjudication by a third study team member AC. Articles that were included in the review were scrutinized based on the reported methodology and demographics to determine if findings were reported from the same studies.

Data extraction and synthesis

Data was extracted from all eligible studies into a piloted spreadsheet by CJT and independently reviewed by SYCY. Extracted variables included study characteristics (author, publication year, country of origin, and study design), population characteristics (sample size, age, cancer type, staging, and other clinical variables), the tools and methods used for measuring symptom burden (presence, severity, and/or frequency) and work outcomes, and the association between symptom burden and work outcomes. Work outcomes were grouped into several categories, which are work status (current employment, RTW, early retirement, and disability), absenteeism, presenteeism (at-work productivity, self-perceived work ability), unpaid work, and other outcomes. Study findings were organized by the type of symptoms and work outcomes evaluated and findings from different articles reporting on the same study were extracted to the same spreadsheet entry. All studies were included in the qualitative synthesis. Meta-analyses and assessment of publication bias were not carried out as a large number of studies did not report effect measures, especially when assessed symptoms were not statistically significant or excluded from the final model presented. Vote counting was performed where the proportion of studies yielding significant findings for each unique association was calculated. The proportions were compared between each unique association.

Quality assessment

The quality of studies and risk of bias were assessed using the Newcastle–Ottawa quality assessment scale (NOS). NOS evaluates studies based on three main aspects—the selection of the study groups, comparability of the groups, and the ascertainment of the exposure and outcome of interest. Assessment was carried out independently by CJ and SYCY and any discrepancies were discussed until a consensus was reached or the opinion of a third study team member AC was sought.

Results

The literature search identified a total of 6583 articles, of which 3217 were duplicates, yielding 3366 articles for assessment of eligibility. Another 3163 articles were excluded based on the title and abstract while 130 were removed during full-text screening. Finally, 73 articles, reporting findings from 68 studies, were selected for review (Fig. 1).

Study and participant characteristics

Collectively, the studies represented 38,603 participants from 24 countries, mostly from Western Europe (35.3%) and North America (27.9%) with the vast majority being high-income nations (89.7%). Forty-two (61.8%) studies were cross-sectional in nature while the remaining 26 (38.2%) were cohort studies. Sample sizes ranged from 22 to 5306, with 11 (16.0%) studies consisting of more than 1000 participants.

The studies included a wide range of cancer types, with 25 (36.8%) consisting of only breast cancer survivors and 17 (25.0%) with patients diagnosed with various cancers. Among studies that reported a summary estimate of the age of participants, slightly more than half (55.9%) reported a mean or median higher than 50 years old. Forty-six studies (67.6%) included an upper age limit as part of the eligibility criteria, which is usually indicative of the retirement age in the region. Fifteen studies (22.1%) comprised of patients with advanced and late-stage disease, among which 5 included patients who had active disease and were still living with cancer. Among 40 studies that reported the time after treatment completion, work outcomes were evaluated at least 1 year after treatment in most studies (60%). The characteristics of the included studies are summarized in Table 1 and listed in Supplementary Material 2.

Quality of study design and analysis

Based on the Newcastle–Ottawa quality assessment scale, most studies were considered to be at low risk of selection bias, with study cohorts that were truly or somewhat representative of the population of interest and controls that were derived from the same community as the participants with significant symptom burden. Confounding by baseline work status or performance was addressed in more than half of the studies (57.4%) by, for example, excluding participants who were not working prior to cancer diagnosis or the use of outcome measures that compared the participants’ current status to pre-cancer levels of work productivity or ability. Most studies (63.2%) adjusted for other potential confounders such as age, occupation type, and time since diagnosis. For cohort studies, the follow-up period was generally adequate (80.8% of studies), but the attrition rate was >20% for half of them. A critical issue that was considered unsatisfactory for a large majority of the studies was the measurement of exposure and outcome, which was largely conducted with
self-reporting tools. The quality assessment of all the studies reviewed is presented in Supplementary Material 3.

**Measurement of symptom burden**

A total of 27 symptoms were identified from the studies reviewed (Supplementary Material 4 and 5). Fatigue was most widely reported (55.9%), followed by depression (50%), cognitive impairment (39.7%), and pain (38.2%). Several symptoms were only investigated in 1 or 2 studies, such as seizures, weight gain, weight loss, drowsiness, hot flashes, rash, sexual dysfunction, and urinary problems. Patient-reported outcomes (PRO) were commonly used in the assessment of symptom burden with validated PRO instruments found in 51 (75.0%) studies while non-validated tools, such as using a single item to inquire the presence of symptoms and visual analog scales, were featured in 14 (20.6%) studies (Table 2). In some studies, although validated instruments were used, the tools were originally developed for the measurement of health-related quality of life in general, and only selected items or domains were relevant to and used for the evaluation of specific symptoms. Clinician-reported outcome measures (16.2%) were also employed, predominantly in the identification of seizures, hot flashes, and lymphedema while performance outcomes, namely, neuropsychological testing and audiometry, were used in the measurement of cognitive impairment and hearing problems, respectively.

**Evaluation of work outcomes**

Work outcomes reported in more than half of the studies were related to current employment status or RTW (70.6%), followed by work ability (14.7%) and work productivity (13.2%). Other work outcomes that were measured included absenteeism, decrease in income level or working...
hours, changes in work scope, and occupational role limitations (Supplementary Material 4 and 5). Unpaid work was not measured in any of the eligible studies. Similar to the measurement of symptom burden, work outcomes were overwhelmingly reported from the patient’s perspective but mostly with instruments with no description of prior validation (77.9%) (Table 3). The exception to this was the evaluation of work ability and work productivity, which were almost entirely measured using the Work Ability Index and the Work Limitations Questionnaire, respectively. Both questionnaires have been validated and extensively used in the cancer population. In 2 studies, work outcomes were determined by clinicians, who assessed work disability status or determined if work restrictions could be lifted based on institution-specified criteria while in 1 study, employment status was directly extracted from an occupational health database containing data reported from employers.

### Association of symptom burden with work outcomes

A total of 68 unique associations between symptoms and work outcomes were identified from the eligible studies (Table 4). A higher symptom burden was generally associated with trends of poorer work outcomes. However, most associations were not found to be statistically significant, and many studies (35.3%) did not report all effect measures, especially if the association was not statistically significant or the symptom was not included in the final analytical model. Additionally, some studies (11.8%) did not report measures of data dispersion.

The association between work status (employment status/RTW or early retirement/work disability) and the following symptoms was examined in more than 10 studies: fatigue, depression, pain, cognitive function, anxiety, nausea/vomiting, and insomnia. However, significant findings were reported in less than half of the studies evaluating the association between work status and these symptoms. Among the remaining associations between symptoms and work status, statistically significant findings were demonstrated in the majority of the studies assessing employment/RTW and oral dysfunction (5 of 5 studies) and employment/RTW and body image issues (4 of 6 studies). However, it should be noted that several dimensions of oral dysfunction were measured with no adjustment for multiple testing.

With regards to work ability and work productivity, none of the associations between work outcomes and

| Table 1 Characteristics of studies reviewed |
|:-------------------------------------------|
| Characteristics                           | N (%)     |
| **Region**                                |           |
| North America                             | 19 (27.9) |
| South America                             | 4 (5.9)   |
| West Europe                               | 24 (35.3) |
| Scandinavia                               | 8 (11.8)  |
| East Europe                               | 1 (1.5)   |
| Middle East                               | 1 (1.5)   |
| South Asia                                | 1 (1.5)   |
| East Asia                                 | 8 (11.8)  |
| Southeast Asia                            | 1 (1.5)   |
| Oceania                                   | 2 (2.9)   |
| **Country income level**                  |           |
| High-income                               | 61 (89.7) |
| Upper middle-income                       | 2 (2.9)   |
| Lower middle-income                       | 6 (8.8)   |
| **Study design**                          |           |
| Cross-sectional                           | 42 (61.8) |
| Prospective cohort                        | 23 (33.8) |
| Retrospective cohort                      | 3 (4.4)   |
| **Number of participants**                |           |
| < 100                                     | 14 (21)   |
| 100 to 500                                | 34 (50)   |
| 501 to 1000                               | 9 (13)    |
| > 1000                                    | 11 (16)   |
| **Age estimate**                          |           |
| Reported as mean/median                   |           |
| > 50 years old                            | 31 (45.6) |
| < 50 years old                            | 22 (31.4) |
| Reported as proportions                   |           |
| Predominantly > 50 years old              | 7 (10.3)  |
| Predominantly < 50 years old              | 5 (7.4)   |
| Unreported                                | 3 (4.4)   |
| **Cancer types**                          |           |
| Breast                                    | 25 (36.8) |
| Head and neck                             | 7 (10.3)  |
| Hematological                             | 6 (8.8)   |
| Gynecological                             | 4 (5.9)   |
| Lung                                      | 2 (2.9)   |
| Prostate                                  | 2 (2.9)   |
| Brain                                     | 2 (2.9)   |
| Colorectal                                | 1 (1.5)   |
| Testicular                                | 1 (1.5)   |
| Thyroid                                   | 1 (1.5)   |
| Various                                   | 17 (25.0) |

1. Sum of percentages exceed 100% as one study was conducted in USA (North America, high-income) and Peru (South America, upper middle-income).
2. Regions based on United Nations Geoscheme and cultural background.
3. Income level based on World Bank classification of countries by
4. Five studies included patients with active disease; 7 excluded while 3 did not report
| Symptom                        | Number of studies with outcomes, N (%) | Total | Examples of patient-reported outcome tools |
|-------------------------------|----------------------------------------|-------|------------------------------------------|
|                               | Performance outcomes | Clinician-reported | Patient-reported | Non-validated | Validated |                                |
| Oral dysfunction              | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 5 (100%)     | 5         | UW-QoL, MDASI-HN, EORTC-QLQ-H&N35 |
| Breast issues                 | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 4 (100%)     | 4         | EORTC-QLQ-B23                   |
| Upper limb problems           | 0 (0%)                   | 4 (28.6%)           | 4 (28.6%)       | 7 (50%)      | 14        | EORTC-QLQ-B23                   |
| Lower limb problems           | 0 (0%)                   | 1 (33.3%)           | 1 (33.3%)       | 1 (33.3%)    | 3         | EORTC-QLQ-CX24                  |
| Cognitive impairment          | 2 (7.4%)                 | 1 (3.7%)            | 4 (14.8%)       | 21 (77.8%)   | 27        | EORTC-QLQ-C30, CFQ, CSC-W, FACT-Cog, AFI |
| Neuropathy                    | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 4 (100%)     | 4         | PAOFI, SCIN, FACT-GOG           |
| Pain                          | 0 (0%)                   | 0 (0%)              | 7 (26.9%)       | 19 (73.1%)   | 26        | EORTC-QLQ-C30, MDASI-ECOG, MDASI-HN, BPI |
| Seizures                      | 0 (0%)                   | 2 (100%)            | 0 (0%)          | 0 (0%)       | 2         | EORTC-QLQ-H&N35, MDASI-HN       |
| Sensory issues                | 1 (16.7%)                | 0 (0%)              | 1 (16.7%)       | 5 (83.3%)    | 6         | EORTC-QLQ-C30, MDASI-ECOG, MDASI-HN |
| Anorexia                      | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 9 (100%)     | 9         | EORTC-QLQ-C30, MDASI-ECOG, MDASI-HN, UW-QoL |
| Weight gain                   | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 1 (100%)     | 1         | EORTC-QLQ-H&N35, MDASI-ECOG     |
| Weight loss                   | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 1 (100%)     | 1         | EORTC-QLQ-H&N35, MDASI-ECOG     |
| Nausea/vomiting               | 0 (0%)                   | 0 (0%)              | 1 (9.1%)        | 10 (90.9%)   | 11        | EORTC-QLQ-C30, MDASI-ECOG       |
| Diarrhea/↑bowel urgency       | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 9 (100%)     | 9         | EORTC-QLQ-C30, MDASI-ECOG, EPIC |
| Constipation                  | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 9 (100%)     | 9         | EORTC-QLQ-C30, MDASI-ECOG       |
| Anxiety                       | 0 (0%)                   | 0 (0%)              | 2 (9.5%)        | 19 (90.5%)   | 21        | UW-QoL, HADS, POMS              |
| Depression                    | 0 (0%)                   | 1 (2.9%)            | 2 (5.9%)        | 31 (91.2%)   | 34        | UW-QoL, HADS, CES-D, BDI, PHQ-9 |
| Body image issues             | 0 (0%)                   | 0 (0%)              | 2 (33.3%)       | 4 (66.7%)    | 6         | UW-QoL, EORTC-QLQ-B23, MDASI-ECOG |
| Coughing                      | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 5 (100%)     | 5         | EORTC-QLQ-H&N35, MDASI-HN, LCSS |
| Dyspnea                       | 0 (0%)                   | 0 (0%)              | 0 (0%)          | 10 (100%)    | 10        | EORTC-QLQ-C30, MDASI-HN, LCSS   |
### Table 2 (continued)

| Symptom                | Number of studies with outcomes, N (%) | Total | Examples of patient-reported outcome tools |
|------------------------|---------------------------------------|-------|-------------------------------------------|
|                        | Performance outcomes                  |       |                                           |
|                        | Clinician-reported                    |       |                                           |
|                        | Patient-reported                      |       |                                           |
|                        | Non-validated                         |       |                                           |
|                        | Validated                             |       |                                           |
| Fatigue                | 0 (0%)                                | 2 (5.3%) | 4 (10.5%) | 33 (86.8%) | 38 | BFI, EORTC-QLQ-C30, FAQ, FACIT-F, MFI |
| Insomnia               | 0 (0%)                                | 0 (0%) | 1 (7.7%) | 12 (92.3%) | 13 | EORTC-QLQ-C30, Pittsburgh Sleep Quality Index |
| Drowsiness             | 0 (0%)                                | 0 (0%) | 0 (0%) | 2 (100%) | 2 | MDASI-ECOG, MDASI-HN |
| Hot flashes            | 0 (0%)                                | 1 (100%) | 0 (0%) | 0 (0%) | 1 | |
| Rash                   | 0 (0%)                                | 0 (0%) | 0 (0%) | 2 (100%) | 2 | MDASI-ECOG |
| Sexual dysfunction     | 0 (0%)                                | 0 (0%) | 0 (0%) | 2 (100%) | 2 | EORTC-QLQ-BR23 |
| Urinary problems       | 0 (0%)                                | 1 (33.3%) | 0 (0%) | 2 (66.7%) | 3 | EPIC |
| Total                  | 2 (2.9%)                              | 11 (16.2%) | 14 (20.6%) | 51 (75.0%) | 68 | |

**Abbreviations:** AFI, Attentional Fatigue Inventory; BDI, Beck Depression Inventory; BPI, Brief Pain Scale; CES-D, Center for Epidemiologic Studies Depression Scale; CFQ, Cognitive Failures Questionnaire; CSC-W, Cognitive Symptom Checklist-Work; EORTC-QLQ-C30, EORTC-QLQ-Core 30; EORTC-QLQ-B23, EORTC-QLQ-Breast 23; EORTC-QLQ-H&N35; EORTC-QLQ-CX24; EPIC, Expanded Prostate Cancer Index Composite; FQ, Fatigue Questionnaire; FAQ, Fatigue Assessment Questionnaire; FACT-Cog, Functional Assessment of Chronic Illness-Fatigue; FACT-GOG, Functional Assessment of Cancer Therapy Gynaecological Oncology Group; HADS, Hospital Anxiety and Depression Scale; MDASI-ECOG, MD Anderson Symptom Inventory-Modified; MDASI-HN, MD Anderson Symptom Inventory-Head and Neck; MFI, Multidimensional Fatigue Inventory; PAOFI, Patient Assessment of Own Functioning Inventory; PHQ-9, Patient Health Questionnaire-9; POMS, Profile of Mood States; SCIN, Scale for Chemotherapy-Induced Long-Term Neurotoxicity; UW-QoL, University of Washington Quality of Life Questionnaire.

### Table 3 Measurement of work outcomes in the studies reviewed

| Work outcome          | Number of studies with outcomes, N (%) | Total | Examples of patient-reported outcome tools |
|-----------------------|---------------------------------------|-------|-------------------------------------------|
|                       | Employer-reported                      |       |                                           |
|                       | Clinician-reported                     |       |                                           |
|                       | Patient-reported                       |       |                                           |
|                       | Non-validated                         |       |                                           |
|                       | Validated                             |       |                                           |
| Absenteeism           | 0 (0%)                                | 0 (0%) | 1 (100%) | 0 (0%) | 1 | |
| Employment/RTW        | 1 (2.1%)                              | 1 (2.1%) | 45 (93.8%) | 1 (2.1%) | 48 | WAI, FACT/GOG |
| Early retirement/disability | 0 (0%)  | 0 (0%) | 1 (10%) | 9 (90%) | 10 | WLQ |
| Work ability          | 0 (0%)                                | 0 (0%) | 1 (11.1%) | 8 (88.9%) | 9 | Occupational Role Questionnaire |
| Work productivity     | 0 (0%)                                | 0 (0%) | 1 (100%) | 1 | 1 | |
| Occupational role limitations | 0 (0%)  | 0 (0%) | 0 (0%) | 1 (100%) | 3 | |
| Changes in work       | 0 (0%)                                | 0 (0%) | 3 (100%) | 0 (0%) | 3 | |
| Income                | 0 (0%)                                | 0 (0%) | 1 (100%) | 0 (0%) | 1 | |
| Working hours         | 0 (0%)                                | 0 (0%) | 1 (100%) | 0 (0%) | 1 | |
| Total                 | 1 (1.5%)                              | 2 (2.9%) | 53 (77.9%) | 18 (26.5%) | 68 | |

**Abbreviations:** FACT/GOG, Functional Assessment of Cancer Therapy Gynaecological Oncology Group; WAI, Work Ability Index; WLQ, Work Limitations Questionnaire.
Symptom burden was investigated in more than 10 studies. Significant findings were demonstrated in more than half of the studies evaluating the association between work ability and fatigue (4 of 7 studies) and work ability and depression (3 of 5 studies). For absenteeism and other work outcomes, not more than 2 studies evaluated the relationship between each work outcome and specific

### Table 4 Number of studies evaluating association between specific symptoms and work outcomes

| Symptom                  | Absenteeism | Work status | Presenteeism | Others |
|--------------------------|-------------|-------------|--------------|--------|
|                          |             | Employment/RTW | Early retirement or disability | Productivity | Work ability | Work changes | Occupational roles limitation | Income | Working hours |
| Oral dysfunction         | 0           | 5           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Work status              |             |              |              |        |             |             |              |         |               |
| Presenteeism             |             |              |              |        |             |             |              |         |               |
| Others                   |             |              |              |        |             |             |              |         |               |
| Breast issues            | 0           | 3           | 0            | 0      | 1           | 0           | 0            | 0       | 0             |
| Upper limb problems      | 0           | 10          | 0            | 1      | 2           | 1           | 0            | 0       | 0             |
| Lower limb problems      | 0           | 2           | 1            | 0      | 0           | 0           | 0            | 0       | 0             |
| Cognitive impairment     | 0           | 18          | 0            | 7      | 4           | 0           | 0            | 0       | 0             |
| Neuropathy               | 0           | 3           | 1            | 0      | 1           | 0           | 0            | 0       | 0             |
| Pain                     | 0           | 21          | 4            | 1      | 1           | 1           | 1            | 0       | 0             |
| Seizures                 | 0           | 2           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Sensory issues           | 0           | 6           | 1            | 0      | 0           | 0           | 0            | 0       | 0             |
| Anorexia                 | 0           | 9           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Weight gain              | 0           | 1           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Weight loss              | 0           | 1           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Nausea/vomiting          | 0           | 11          | 0            | 0      | 0           | 1           | 1            | 0       | 0             |
| Diarrhea/↑Bowel urgency  | 0           | 9           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Constipation             | 0           | 9           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Anxiety                  | 0           | 14          | 0            | 5      | 2           | 2           | 1            | 0       | 0             |
| Depression               | 1           | 23          | 3            | 6      | 5           | 2           | 1            | 1       | 1             |
| Body image issues        | 0           | 6           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Coughing                 | 0           | 5           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Dyspnea                  | 0           | 10          | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Fatigue                  | 1           | 29          | 2            | 4      | 7           | 1           | 1            | 0       | 0             |
| Insomnia                 | 0           | 11          | 1            | 1      | 0           | 1           | 1            | 0       | 0             |
| Drowsiness               | 0           | 2           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Hot flashes              | 1           | 0           | 0            | 1      | 0           | 0           | 0            | 0       | 0             |
| Rash                     | 0           | 2           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Sexual dysfunction       | 0           | 2           | 0            | 0      | 0           | 0           | 0            | 0       | 0             |
| Urinary problems         | 0           | 3           | 0            | 0      | 1           | 0           | 0            | 0       | 0             |

Cells shaded in green indicate that more than half of the studies evaluating the association reported significant findings (excluding associations investigated by 2 or less studies) while cells shaded in blue indicate that more than one-third of the studies evaluating the association reported significant findings (excluding associations investigated by 2 or less studies)
symptoms. No significant associations were detected for studies evaluating absenteeism, income, and working hours.

Symptoms with notable findings in the review are summarized below. A complete description of findings for each association between symptom and work outcome identified from the literature can be found in the Supplementary Material 6.

### Fatigue and insomnia

The impact of fatigue on a range of work outcomes was evaluated in 38 (55.9%) studies, in which fatigue was predominantly assessed with validated PRO measures. The studies included survivors of various cancers, mostly previously diagnosed with breast cancer. More than half of the studies that identified work ability as an outcome found a significantly negative association between symptom severity and work outcome [16–19] while only one-third of the studies that investigated work status yielded significant results [20–30]. None of the studies evaluating insomnia showed significant findings.

### Anxiety and depression

Anxiety and depression were evaluated in approximately 21 (30.9%) and 34 (50.0%) studies, respectively, and were often investigated in the same studies due to the use of PRO tools that measure both constructs. The most common outcome of interest was employment/RTW but work ability, productivity, and other work outcomes were also examined. Similar to fatigue, approximately one-third of the studies evaluating depression and work status demonstrated significant findings [18, 20, 21, 27, 31–37] but more than half of the studies evaluating work ability yielded significantly negative associations between depression and work ability [16–18]. In contrast, studies consistently shown non-significant findings when the association of anxiety and various work outcomes was evaluated.

### Pain

Studies evaluating the impact of pain on work outcomes largely focused on the work status of participants, evaluating employment status/RTW or early retirement/disability. Notably, PROs used to measure the presence or severity of pain in a quarter of the studies were not validated tools [22, 31, 38–40]. Studies with more than 1000 participants consistently showed that patients with more severe pain were less likely to return to work or be employed [28, 40–43]. Studies investigating other work outcomes mostly did not detect any significant relationship [44–46].

### Cognitive impairment

Work outcomes that were examined in association with cognitive impairment included employment status, work productivity, and work ability. Most studies evaluating work status reported effect measures that were not statistically significant [20, 22, 23, 26, 33, 36, 47–53] or of small magnitude [29, 37, 54]. An exception to this was Dieluweit et al., where survivors of various cancers with cognitive impairment had half the odds of being employed more than 5 years after diagnosis compared to those without [55]. In contrast, several studies consistently demonstrated that poorer cognitive function was correlated to lower levels of work ability or work productivity, predominantly among breast cancer survivors [17, 56–58]. Specific domains of cognitive function were also investigated in a number of studies, such as attention, executive function, memory, and verbal fluency, but no consistent trends could be observed. One study that employed performance outcomes (neuropsychological testing) as an indicator of cognitive function reported no significant impact of cognitive impairment on employment status and work ability [50].

### Nausea and vomiting

The association between nausea and vomiting and work status was assessed in 11 (16.2%) of the studies reviewed. Although the target population was no longer on active antineoplastic treatment and hence not expected to be affected by nausea and vomiting, 3 studies demonstrated significant findings [20, 37, 46]. For example, Steiner et al. reported that up to 46% and 55% of survivors who experienced changes at work or had limitations in occupational roles complaint of nausea and vomiting [46]. Interestingly, in this study, approximately 20% or participants with no work issues cited nausea and vomiting as a concern as well [46].

### Oral dysfunction

Five (7.4%) studies investigated the association of employment status with different aspects of oral health, including dry mouth, sticky saliva, teeth problems, and functional issues (speaking, swallowing, and chewing), mostly among head and neck cancer survivors. The dimensions examined depended on the PRO tool that was used. Significant associations were observed in all studies, mainly with dry mouth, sticky saliva, and chewing function [23, 37, 48, 53, 59]. Patients who reported a higher level of symptom burden in these domains had lower odds of employment.
Body image issues

A few studies evaluated the impact of body image issues on employment and RTW using PRO instruments. Half of the studies demonstrated significant associations [29, 47, 59]. The largest effect size was reported by Chen et al. where cancer survivors with scarring had 3 times the odds of being denied a job due to their medical history compared to those without [59].

Discussion

This systematic review summarized the association of cancer-related symptom burden and work outcomes among cancer survivors who have completed primary antineoplastic treatment. To the best of our knowledge, this is the first systematic review that has included all cancer-related symptoms or complications that have been examined in the literature in association with work outcomes. In this review, body image issues and oral dysfunction were consistently demonstrated to be associated with lower employment rates, while fatigue and depression were linked to lower levels of work ability.

Among the studies included in this review, work status (employment, RTW, early retirement, and work disability) was most commonly studied. However, it should be noted that work status alone only captures extreme consequences where there is a complete loss of employment. Cancer survivors who remain employed can experience inferior outcomes at work, manifesting as decreased productivity, reduced working hours, and absenteeism [5]. This was evident from our review where cognitive impairment, fatigue, and depression were more consistently shown to be associated with reduced work ability or productivity than to lower employment rates. It is also important to emphasize that measures of unpaid work, such as household chores, caregiving, childcare, or volunteering, were not investigated in any of the studies reviewed. These outcomes hold significant value to patients and are an important component of productivity valuation [60]. Therefore, future studies should consider a wider range of work outcomes beyond changes in work status to comprehensively describe poor work outcomes that result from cancer-related complications. Focusing on work status alone may risk neglecting cancer survivors who are employed but face difficulties at work or reduced productivity beyond the scope of paid work.

Our review also showed that symptom burden was overwhelmingly measured using self-reported outcomes. Although patient-reported instruments are often considered to be at high risk of measurement bias, these tools have been shown to capture symptom burden among cancer survivors more accurately than clinician-reported outcomes [61]. Patient-reported outcomes are also more relevant than performance outcomes as they are closely related to how cancer-related complications affect daily activities from the perspective of the patients themselves. Nevertheless, it is important to select PROs that have been validated in the population of interest. In a number of the studies reviewed, single items or subscales from health-related quality-of-life questionnaires were used to measure symptom burden. This approach should be avoided unless validation of these components has previously been carried out. Furthermore, as symptom burden can be measured in terms of multiple dimensions, such as severity or frequency, further investigation should be carried out to ascertain if the relationship between symptom burden and work outcomes changes depending on how the former is quantified. PROs that have established clinically important thresholds should also be considered to enable comparison between studies and pooling of data for quantitative synthesis.

Contrary to expectations, significant relationships were not consistently demonstrated in most of the studies evaluating cancer-related complications that have been widely reported to persist among cancer survivors beyond the treatment phase, such as cognitive impairment, fatigue, pain, anxiety, and depression. Only approximately one-third of studies evaluating work status and fatigue or depression showed significant associations while a small proportion of studies assessing anxiety symptoms and cognitive impairment reported significant findings. This could potentially be due to the influence of psychosocial and interpersonal factors, such as family support and professional relationships at the workplace, on how cancer-related symptoms impact work outcomes. Although these factors have been postulated to affect work outcomes, they are generally difficult to quantify and control for in studies, leading to wide variability in the effect measures estimated and the lack of statistically significant findings. An alternative explanation was the use of vote counting in this review, where the proportions of studies reporting significant findings for each symptom were compared to identify symptoms consistently associated with poor work outcomes. Ideally, estimates from studies should be pooled in meta-analyses for the purpose of quantitative synthesis [62]. However, this approach was not feasible as almost half of the studies reviewed did not report all effect measures or measures of dispersion, especially if symptoms were not significantly associated with work outcomes or were excluded during model building. A pooled estimate from the reported effect measures would thus be biased away from the null. While vote counting was the best possible approach to identify trends in this review, the strength of the relationship between symptom burden and work outcomes was most likely underestimated [62]. Non-significant findings in individual studies could be due to the lack of statistical power rather than the absence of a true effect, particularly as the number of eligible studies

 Springer
increased [62]. This was supported by an observation in our review where reported significant associations between pain and employment/RTW all consisted of samples of more than 1000 participants. To allow quantitative synthesis of findings and robust conclusions to be drawn from pooled data, future studies should report all results, including those from univariate analysis and model building exercises.

There is a continual need for more research to demonstrate how specific cancer-related symptoms influence work and employment among cancer survivors. Most of the associations between specific symptoms and work outcomes were only evaluated in a relatively small number of studies, with 47 of 68 of the unique associations identified evaluated in less than 5 studies. Associations that were found to be consistently significant in the majority of studies were also investigated in less than 10 studies each. The majority of the studies included were also cross-sectional in nature. Due to the lack of longitudinal observations, it is not possible to rule out reverse causality, where the symptom burden observed could have resulted from inferior work outcomes. This is plausible for a number of psychological symptoms such as depression and anxiety, suggesting the need for more prospective cohort studies examining these symptoms. Furthermore, most of the eligible studies were conducted in high-income countries predominantly in Europe or the USA, where labor market conditions, work demands, and cultural values may not be representative of all settings. More work should be carried out to validate if findings from existing studies are generalizable to lower-income or non-Western countries. Exploring these research gaps will allow a more comprehensive picture of how cancer-related symptom burden influences work outcomes among cancer survivors.

A potential limitation of this review was the lack of restrictions on the cancer diagnoses of participants recruited in the studies, which can increase the heterogeneity of the pooled findings. The incidence of certain symptoms, or the association between symptoms and work outcomes, may also be unique to specific patient populations. For example, oral dysfunction was mainly investigated and found to be significantly associated with poor work outcomes among survivors of head and neck cancer. The inclusion of all cancer diagnoses, however, ensured that the findings of this review would be beneficial to the wider survivor population and can assist the development of rehabilitative services that cater to all survivors regardless of cancer diagnoses. Cancer-related complications that are demonstrated to have a consistent and strongly negative impact on work outcomes, even if unique to a particular group of cancer survivors, are still important to address in work rehabilitation programs.

As survivorship care improved over the last two decades, interventions have been established for various cancer-related complications that plague cancer survivors, ranging from pharmacotherapeutic options such as non-opioid and opioid analgesics for pain [63] to non-pharmacological approaches, for example, cognitive training for cognitive impairment [64], speech rehabilitation for oral dysfunction [65], and cognitive behavioral therapy for depressive and anxiety symptoms [66]. Corroborating our observation that several different symptoms are linked to poor work outcomes, a review of current evidence suggested that only a multidisciplinary approach incorporating physical, psychoeducational, and medical interventions is effective in improving RTW among cancer survivors [9]. On a health-system level, findings from this review are therefore highly valuable to guide the selection of components to be prioritized when designing complex interventions for work rehabilitation, ensuring the efficient use of resources. This is particularly important in resource-constrained settings where the focus of oncology care is often almost entirely on antineoplastic treatment with limited capacity available for survivorship services [67]. From a clinical perspective, our findings also serve to increase the awareness of care providers to discuss any impact on employment or work when cancer survivors present with symptoms that are linked to poor work outcomes.

In conclusion, this systematic review has comprehensively investigated the extent to which different cancer-related symptoms significantly impact work outcomes of cancer survivors. While a range of complications, including body image issues, oral dysfunction, fatigue, and depression, were found to be linked to poor work outcomes among cancer survivors, our review has indicated that more studies with comprehensively reported findings are needed to draw robust conclusions. A wider range of work outcomes should also be considered, including absenteeism, presenteeism, and unpaid work while symptom burden should be measured with PRO tools that have been validated in the cancer population. The findings of this review can assist clinicians and policy makers in making informed decisions about the symptoms that adversely affect work outcomes and should be targeted in work rehabilitation programs.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11764-021-01097-5.

**Data availability** The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate** This was a systematic review and required no ethical approval or informed consent.

**Conflict of interest** The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol [Internet]. Elsevier Ireland Ltd; 2011;77:109–30. Available from: https://doi.org/10.1016/j.critrevonc.2010.01.004

2. Stone DS, Ganz PA, Pavlish C, Robbins WA. Young adult cancer survivors and work: a systematic review. J Cancer Surviv [Internet]. 2017;11:765–81. Available from: http://link.springer.com/hdoj/10.1007/s11764-017-0614-3

3. Hornbrook MC, Grant M, Wendel C, Bulkey JE, McMullen CK, Alschuler A, et al. Rectal cancer survivors’ participation in productive activities. Perm J [Internet]. 2018;22:17–022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29236653

4. Guy GP, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol [Internet]. 2013;31:3749–57. Available from: http://ascopubs.org/doi/https://10.1200/JCO.2013.49.1241

5. Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv [Internet]. 2010;4:415–37. Available from: http://link.springer.com/doi/10.1007/s11764-010-0154-6

6. Parsons HM, Harlan LC, Lynch CF, Hamilton AS, Wu X-C, Kato I, et al. Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol [Internet]. 2012;30:2393–400. Available from: http://ascopubs.org/doi/https://10.1200/JCO.2011.39.6333

7. Ketterl TG, Syrjala KL, Casillas J, Jacobs LA, Palmer SC, McCabe MS, et al. Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer [Internet]. 2019; Available from: http://doi.wiley.com/https://10.1002/cncr.31985

8. Silver JK, Baima J, Newman R, Galantino M, Lou, Shackney LD. Cancer rehabilitation may improve function in survivors and decrease the economic burden of cancer to individuals and society. Work [Internet]. 2013;46:455–72. Available from: https://www.medra.org/servertaliasResolver?urlalias=iospress&doi=https://https://10.3233/WOR-131755

9. de Boer AG, Taskila TK, Tamminga SJ, Feuerstein M, Frings-Dresen MH, Verbeek JH. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev [Internet]. 2015; Available from: http://doi.wiley.com/https://10.1002/14651858.CD007569.pub3

10. Cocchiara RA, Sciarra I, D’Egidio V, Sestili C, Mancino M, Backhaus I, et al. Returning to work after breast cancer: a systematic review of reviews. Work [Internet]. 2018;61:463–76. Available from: https://www.medra.org/servertaliasResolver?alias=iospress&doi=https://https://10.3233/WOR-182810

11. van Muijen P, Weevers NLEC, Snels IAK, Duijts SFA, Bruinvels DJ, Schellart AJM, et al. Predictors of return to work and employment in cancer survivors: a systematic review. Eur J Cancer (Engl) [Internet]. 2013;22:144–60. Available from: http://doi.wiley.com/https://10.1111/ecc.12033

12. Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi MC, Pellegrini M, Vicentini M, et al. Return to work in European cancer survivors: a systematic review. Support Care Cancer [Internet]. 2018;26:2983–94. Available from: http://link.springer.com/https://10.1007/s00520-018-4270-6

13. Zomkowski K, Cruz de Souza B, Pinheiro da Silva F, Moreira GM, de Souza Cunha N, Sperandio FP. Physical symptoms and working performance in female breast cancer survivors: a systematic review. Disabil Rehabil [Internet]. 2018;40:1485–93. Available from: https://www.tandfonline.com/doi/full/https://doi.org/10.1080/09638288.2017.1300950

14. Bijker R, Duijts SFA, Smith SN, de Wildt-Liesveld R, Anema JR, Regeer BJ. Functional impairments and work-related outcomes in breast cancer survivors: a systematic review. J Occup Rehabil [Internet]. Springer US; 2017:0:0. Available from: https://doi.org/10.1007/s10926-017-9736-8

15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ [Internet]. 2009;339:b2535–b2535. Available from: https://www.bmj.com/lookup/https://10.1136/bmj.b2535

16. Ho PJ, Hartman M, Gernaat SAM, Cook AR, Lee SC, Hupkens L, et al. Associations between workability and patient-reported physical, psychological and social outcomes in breast cancer survivors: a cross-sectional study. Support Care Cancer [Internet]. 2018;26:2815–24. Available from: http://link.springer.com/https://10.1007/s00520-018-4132-2

17. Dorland HF, Abma FI, Van Zon SKR, Stewart RE, Amick BC, Ranchor AV, et al. Fatigue and depressive symptoms improve but remain negatively related to work functioning over 18 months after return to work in cancer patients. J Cancer Surviv. 2018;12:371–8.

18. Dahl AA, Fosså SD, Lie HC, Loge JH, Reinertsen KV, Ruud E, et al. Employment status and work ability in long-term young adult cancer survivors. J Adolesc Young Adult Oncol. 2019;8:304–11.

19. Wolvers MDJ, Leenssen MCJ, Groeneveld IF, Frings-Dresen MHW, De Boer AGEM. Longitudinal associations between fatigue and perceived work ability in cancer survivors. J Occup Rehabil [Internet]. Springer US; 2019;29:540–9. Available from: https://doi.org/10.1007/s10926-018-9814-6

20. Duijts SFA, Kieffer JM, van Muijen P, van der Beek AJ. Sustained employability and health-related quality of life in cancer survivors up to four years after diagnosis. Acta Oncol (Madr). 2017;56:174–82.

21. Tamminga SJ, Bültmann U, Husson O, Kuipjens JLP, Frings-Dresen MHW, de Boer AGEM. Employment and insurance outcomes and factors associated with employment among long-term thyroid cancer survivors: a population-based study from the PROFILES registry. Qual Life Res. 2016;25:997–1005.

22. Pryce J, Munir F, Haslam C. Cancer survivorship and work: symptoms, supervisor response, co-worker disclosure and work adjustment. J Occup Rehabil [Internet]. 2007;17:83–92. Available from: http://link.springer.com/https://10.1007/s10926-006-9040-5

23. Tevaarwerk AJ, Lee JW, Sesto ME, Buhr KA, Cleeland CS, Manola J, et al. Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study. J Cancer Surviv [Internet]. 2013;7:191–202. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf.
24. Murray K, Lam KBH, McLoughlin D, Sadhra SS. Factors in removing job restrictions for cancer survivors in the United Kingdom Royal Air Force. J Occup Rehabil [Internet]. Springer US; 2019;29:25–30. Available from: https://doi.org/10.1007/s10926-018-9758-x

25. Behringer K, Goergen H, Müller H, Thielan I, Brillant C, Kreissl S, et al. Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol. 2016;34:4329–37.

26. Kiserud CE, Fagerli UM, Smeland KB, Fluge Bervsenden H, Kvalay S, et al. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. Acta Oncol (Mad). 2016;55:547–53.

27. Schmidt ME, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019;28:1–11.

28. Lindbohm ML, Kuosma E, Taskila T, Hietanen P, Carlsten K, Gudbergsøn S, et al. Early retirement and non-employment after breast cancer. Psychooncology. 2014;23:634–41.

29. Zomkowski K, Wittkopf PG, Baugarten Huguen Back B, Bergmann A, Dias M, Sperandio FF. Pain characteristics and quality of life of breast cancer survivors that return and do not return to work: an exploratory cross-sectional study. Disabil Rehabil [Internet]. Taylor & Francis; 2020;0:1–6. Available from: https://doi.org/10.1080/09638288.2020.1759150

30. Ekenga CC, Pérez M, Margenthaler JA, Jeffe DB. Two years of follow-up: a comparison with age-matched controls. 2019;124:2026–35.

31. Landeiro LCG, Gagliato DM, Fêde AB, Fraile NM, Lopez RM, da Fonseca LG, et al. Return to work after breast cancer diagnosis: an observational prospective study in Brazil. Cancer. 2018;124:4700–10.

32. Koch R, Wittkendt C, Altendorf-Hofmann A, Singer S, Guntinas-Lichius O. Employment pathways and work-related issues in head and neck cancer survivors. Head Neck [Internet]. 2015;37:585–93. Available from: http://doi.wiley.com/https://doi.org/10.1002/hed.23640

33. Spelten ER, Verbeek JHAM, Uitterhoeve AJ, Ansink AC, Van Der Lelie J, De Reijke TM, et al. Cancer, fatigue and the return of patients to work - a prospective cohort study. Eur J Cancer. 2013;49:1562–7.

34. Magyari F, Kósa K, Berecz R, Illés A, Militényi Z, Simon Z, et al. Employment status and health related quality of life among Hodgkin-lymphoma survivors’ - results based on data from a major treatment center in Hungary. Health Qual Life Outcomes. Health and Quality of Life Outcomes; 2017;15:1–9.

35. Dahl AA, Bentzen AG, Fosså SD, Hess SL, Steen R, Kiserud CE. Long-term cervical cancer survivors on disability pension: a subgroup in need of attention from health care providers. J Cancer Surviv. 2020;14:578–85.

36. Dumas A, Luis IV, Bovagniet T, El Mouhebb M, Di Meglio A, Pinto S, et al. Impact of breast cancer treatment on employment: results of a multicenter prospective cohort study (CANTO). J Clin Oncol. 2020;38:734–43.

37. Check DK, Hutcheson KA, Poisson LM, Pocobelli G, Sakoda LC, Zaveri J, et al. Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer. Head Neck. 2019;41:3948–59.

38. Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak J, Frimat P, Leroyer A. Factors related to return to work by women with breast cancer in northern France. J Occup Rehabil. 2010;20:49–58.

39. Azarkish F, Najmabadi KM, Roudsari RL, Shandiz FH. Factors related to return to work in women after breast cancer in Iran. Iran Red Crescent Med J. 2015;17.

40. Cox-Martin E, Anderson-Mellies A, Borges V, Bradley C. Chronic pain, health-related quality of life, and employment in working-age cancer survivors. J Cancer Surviv. 2020;14:179–87.

41. Mehnert A, Barth J, Gaspar M, Leibbrand B, Kegel CD, Bootsveld W, et al. Predictors of early retirement after cancer rehabilitation—a longitudinal study. Eur J Cancer Care (Engl). 2017;26:1–9.

42. Kenzik K, Pisu M, Johns SA, Baker T, Oster RA, Kvale E, et al. Unresolved pain interference among colorectal cancer survivors: implications for patient care and outcomes. Pain Med [Internet]. 2015;16:1410–25. Available from: https://academic.oup.com/painmedicine/article-lookup/doi/https://doi.org/10.1111/pme.12727

43. Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, et al. Relationship of cisplatin-related adverse health outcomes with disability and unemployment among testicular cancer survivors. JNCI Cancer Spectr. 2020;4:1–13.

44. Musti MA, Collina N, Stivanello E, Bonfiglioli R, Giordani S, Morelli C, et al. Perceived work ability at return to work in women treated for breast cancer: a questionnaire-based study. Med del Lav. 2018;109:407–19.

45. Calvlo L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010;52:219–27.

46. Steiner JF, Cavender TA, Nowels CT, Beatty BL, Bradley CJ, Fairclough DL, et al. The impact of physical and psychosocial factors on work characteristics after cancer. Psychooncology [Internet]. 2008;17:138–47. Available from: http://doi.wiley.com/https://doi.org/10.1002/pon.1204

47. Lee MK, Kang HS, Lee KS, Lee ES. Three-year prospective cohort study of factors associated with return to work after breast cancer diagnosis. J Occup Rehabil. Springer US; 2017;27:547–58.

48. Agarwal J, Krishnatry R, Chaturvedi P, Ghosh-Laskar S, Gupta T, Budruckar A, et al. Survey of return to work of head and neck cancer survivors: a report from a tertiary cancer center in India. Head Neck [Internet]. 2017;39:893–9. Available from: http://doi.wiley.com/https://doi.org/10.1002/hed.24703

49. Yoo SH, Yun YH, Park S, Ae Kim Y, Park SY, Bae DS, et al. The correlates of unemployment and its association with quality of life in cervical cancer survivors. J Gynecol Oncol. 2013;24:367–75.

50. Nieuwenhuijzen K, de Boer A, Spelten E, Sprangers MAG, Verbeek JHAM. The role of neuropsychological functioning in cancer survivors’ return to work one year after diagnosis. Psychooncol. 2009;18:589–97.

51. Cooper AF, Hankins M, Rixon L, Eaton E, Grunfeld EA. Distinct work-related, clinical and psychological factors predict return to work following treatment in four different cancer types. Psychooncol. 2013;22:659–67.

52. Kim YA, Yun YH, Chang YJ, Lee J, Kim MS, Lee HS, et al. Employment status and work-related difficulties in lung cancer survivors compared with the general population. Ann Surg. 2014;259:569–75.

53. Verdonck-de Leeuw IM, van Bleek W-J, René Leemans C, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncol [Internet]. Elsevier Ltd; 2010;46:56–60. Available from: https://doi.org/10.1016/j.oraloncology.2009.11.001

54. Boscher C, Joly F, Clarisse B, Humbert X, Grellard JM, Binarelli G, et al. Perceived cognitive impairment in breast cancer survivors and its relationships with psychological factors. Cancers (Basel). 2020;12:1–13.
55. Dieluweit U, Debatin K-M, Grabow D, Kaatsch P, Peter R, Seitz DCM, et al. Educational and vocational achievement among long-term survivors of adolescent cancer in Germany. Pediatr Blood Cancer [Internet]. 2011;56:432–8. Available from: http://doi.wiley.com/https://doi.org/10.1002/pbc.22806

56. Von Ah D, Storey S, Crouch A. Relationship between self-reported cognitive function and work-related outcomes in breast cancer survivors. J Cancer Surviv. 2018;12:246–55.

57. Von Ah D, Storey S, Crouch A, Johns SA, Dodson J, Dutkevitch S. Relationship of self-reported attentional fatigue to perceived work ability in breast cancer survivors. Cancer Nurs. 2017;40:464–70.

58. Zeng Y, Cheng ASK, Feuerstein M. Cognitive limitations at work among employed breast cancer survivors in china. Rehabil Nurs. 2017;42:347–53.

59. Chen SC, Huang BS, Hung TM, Lin CY, Chang YL. Impact of physical and psychosocial dysfunction on return to work in survivors of oral cavity cancer. Psychooncology. 2019;28:1910–7.

60. Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc Sci Med [Internet]. 2015;144:127–37. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0277953615301131

61. Gordon B-BE, Chen RC. Patient-reported outcomes in cancer survivorship. Acta Oncol (Madr) [Internet]. 2017;56:166–73. Available from: https://www.tandfonline.com/doi/full/https://doi.org/10.1080/0284186X.2016.1268265

62. Bordenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2009. Available from: http://doi.wiley.com/https://doi.org/10.1002/9780470743386

63. Paice JA, Portenoy R, Llacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol [Internet]. 2016;34:3325–45. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2016.68.5206

64. Zeng Y, Dong J, Huang M, Zhang J, Zhang X, Xie M, et al. Non-pharmacological interventions for cancer-related cognitive impairment in adult cancer patients: a network meta-analysis. Int J Nurs Stud [Internet]. 2020;104:103514. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0020748919303219

65. Clarke P, Radford K, Coffey M, Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol [Internet]. 2016;130:S176–80. Available from: https://www.cambridge.org/core/product/identifier/S0022215116000608/type/journal_article

66. Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, et al. Management of depression in patients with cancer: a clinical practice guideline. J Oncol Pract [Internet]. 2016;12:747–56. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JOP.2016.011072

67. Anwar SL, Adistyawan G, Wulaningsih W, Gutenbrunner C, Nugraha B. Rehabilitation for cancer survivors. Am J Phys Med Rehabil [Internet]. 2018;97:764–71. Available from: https://journals.lww.com/00002060-201810000-00012

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.